[In vitro study on arsenic trioxide-inducing apoptosis in primary acute promyelocytic leukemie cells]

W Tang; G Chen; Z Shen; L Chen; X Shi; P Jia; G Shi; J Ni; S Chen; Z Wang

[In vitro study on arsenic trioxide-inducing apoptosis in primary acute promyelocytic leukemie cells]

Zhonghua Xue Ye Xue Za Zhi. 1997 Dec;18(12):623-6.

[Article in Chinese]

Authors

W Tang¹, G Chen, Z Shen, L Chen, X Shi, P Jia, G Shi, J Ni, S Chen, Z Wang

Affiliation

¹ Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025.

PMID: 15625759

Abstract

Objective: To illustrate mechanisms of arsenic trioxide(As2O3) in the treatment of acute promyelocytic leukemia (APL).

Methods: Cell-DNA content distribution, CD11b and CD33 antigens and nitroblue tetrazolium (NBT) reduction were evaluated in fresh APL cells from six APL patients treated in vitro with As2O3.

Results: As2O3 had double effects on the cells inducing apoptosis and inducing partial differentiation at higher and at lower drug concentrations, respectively. As2O3 (0.1 approximately 2.0 micromol/L) could rapidly modulate and degrade APL-specific marker molecule PML-RARalpha protein, which could play an important role in the effects of As2O3 on APL cells.

Conclusion: As2O3 had double effects (induction of apoptosis and partial differentiation) on APL cells through the modulation and degradation of PML-RARalpha proteins.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Apoptosis / drug effects*
Arsenic Trioxide
Arsenicals / pharmacology*
Cell Proliferation / drug effects
Cells, Cultured
Gene Expression Regulation, Neoplastic / drug effects
Humans
Leukemia, Promyelocytic, Acute / genetics
Leukemia, Promyelocytic, Acute / pathology*
Oncogene Proteins, Fusion / metabolism
Oxides / pharmacology*

Substances

Arsenicals
Oncogene Proteins, Fusion
Oxides
promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
Arsenic Trioxide